Home  /  Resource Library  /  Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run in of the phase 3 SYMPATICO study

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run in of the phase 3 SYMPATICO study

Results of a phase III trial investigating ibrutinib combined with venetoclax for treatment of relapsed mantle cell lymphoma.